In brief: Agenix files for Canadian trials; Rockeby to appoint Chinese distributor
Tuesday, 31 August, 2004
Brisbane’s Agenix (ASX: AGX, NASDAQ OTC: AGXLY) announced today it had filed a Clinical Trial Application (CTA) with Health Canada in preparation for the Phase II clinical trials of its ThromboView blood clot imaging technology.
This follows last week’s filing of an Investigational New Drug (IND) application for Phase II trials with the US Food and Drug Administration (FDA).
The initial deep vein thrombosis (DVT) trial will involve 11 principal investigators, a core nuclear medicine group and academic and commercial research groups to conduct the trials. Up to 180 suspected DVT patients will take part in the trials.
Rockeby appoint Chinese distributor
Sydney's Rockeby biomed (ASX:RBY) has signed a memorandum of understanding with specialist Chinese women’s medicine and healthcare company, Hua Han Bio-Pharmaceutical for the rollout of its thrush diagnostic CanDia5 throughout mainland China.
Hua Han Bio-Pharmaceutical is listed on Main Board of the Hong Kong Stock Exchange. Hua Han will manage the registration of CanDia5 at its own expense.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...
